Date:December 26, 2012

ZoAnn Dreyer, MD

ZoAnne Dreyer, M.D.Co-Director, Long Term Survivor Program
Clinical Leader, Long Term Survivor Clinic
Texas Children’s Cancer Center
Texas Children’s Hospital

Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine

Dr. ZoAnn Dreyer
6701 Fannin Street, Suite 1510.16
Houston, TX 77030

Phone: 832-822-4209
Fax: 832-825-1456

About Dr. ZoAnn Dreyer

Dr. ZoAnn Dreyer is a Co-Director of the Long Term Survivor Program where she acts as Clinical Leader of the Long Term Survivor Clinic at Texas Children’s Cancer Center. Over 1,000 childhood cancer survivors are evaluated every one to two years for delayed effects of their prior cancer therapy. Survivors are patients who are more than five years from their diagnosis and off therapy at least two years. There is no upper age limit for survivors followed in the clinic. Survivors are now invited to become participants in a novel program, the Passport for Care® Application.

Dr. ZoAnn Dreyer is a member of the Leukemia Program and the Long Term Survivor Program.

Clinical Research Interests

Dr. ZoAnn Dreyer’s additional clinical interests include acute lymphoid leukemia in infants younger than one year old. She was the principal investigator for an innovative, nationwide treatment protocol for these infants that have resulted in dramatically improved survival rates. She is currently principal investigator of a new pilot study using intensified asparaginase in patients with high risk ALL.

Dr. Dreyer earned her bachelor’s degree and medical degree from the University of California, Davis, Calif. She served her internship, residency and postdoctoral fellowship at Baylor College of Medicine, one of the nation’s leading medical schools.


M.D., University of California-Davis School of Medicine
Residency and Fellowship, Baylor College of Medicine

Board Certifications

American Board of Pediatrics
American Board of Pediatrics-Hematology/Oncology

Selected Memberships

President, Gulf Coast Hematology Society
Member, American Society of Pediatric Hematology/Oncology (ASPHO)
Member, American Society of Hematology (ASH)
Member, American Society of Clinical Oncology (ASCO)

Clinical Interests

Late Effects